Anixa Biosciences Net Income Over Time
| ANIX Stock | USD 2.82 0.01 0.36% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Anixa Biosciences Performance and Anixa Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anixa Biosciences. If investors know Anixa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anixa Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Anixa Biosciences's market price often diverges from its book value, the accounting figure shown on Anixa's balance sheet. Smart investors calculate Anixa Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Anixa Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Anixa Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anixa Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Anixa Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Anixa Biosciences and related stocks such as Entera Bio, Inovio Pharmaceuticals, and TuHURA Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTX | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (1.2 M) | (11.2 M) | (10.3 M) | (10.8 M) | (10 M) | (12.2 M) | (13.1 M) | (8.9 M) | (9.5 M) | (8.6 M) | (9 M) |
| INO | (6.6 M) | (15.3 M) | (19.7 M) | (66 M) | (36.1 M) | (29.2 M) | (73.7 M) | (88.2 M) | (97 M) | (119.4 M) | (166.4 M) | (303.7 M) | (279.8 M) | (135.1 M) | (107.3 M) | (96.5 M) | (101.4 M) |
| HURA | (5.6 K) | (18.9 K) | (8.3 M) | (8.3 M) | (4.3 M) | (8.9 M) | (8.1 M) | (11.1 M) | (8 M) | (9.1 M) | (38.3 M) | (7 M) | (9.4 M) | (29.3 M) | (21.7 M) | (19.5 M) | (18.5 M) |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| VTGN | (4.8 K) | (12.2 M) | (12.9 M) | (3 M) | (13.9 M) | (47.2 M) | (10.3 M) | (14.3 M) | (24.6 M) | (20.8 M) | (17.9 M) | (47.8 M) | (59.2 M) | (29.4 M) | (51.4 M) | (46.3 M) | (44 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| AGEN | (18.1 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.5 M) | (87.9 M) | (127 M) | (120.7 M) | (159.7 M) | (107.7 M) | (180.9 M) | (23.9 M) | (220.1 M) | (245.8 M) | (227.2 M) | (204.5 M) | (194.3 M) |
Anixa Biosciences and related stocks such as Entera Bio, Inovio Pharmaceuticals, and TuHURA Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Anixa Biosciences financial statement analysis. It represents the amount of money remaining after all of Anixa Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Anixa Biosciences | ANIX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3150 Almaden Expressway, |
| Exchange | NASDAQ Exchange |
USD 2.82
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.